Could Radiomic Signature on Chest CT Predict Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer?

被引:1
|
作者
Cangir, Ayten Kayi [1 ]
Koksoy, Elif Berna [2 ]
Orhan, Kaan [3 ]
Ozakinci, Hilal [4 ]
Coruh, Aysegul Gursoy [5 ]
Gumustepe, Esra [6 ]
Kahya, Yusuf [1 ]
Ibrahimov, Farrukh [1 ]
Buyukceran, Emre Utkan [5 ]
Akyurek, Serap [5 ]
Sak, Serpil Dizbay [4 ]
机构
[1] Ankara Univ, Fac Med, Med Design Applicat & Res Ctr MEDITAM, Dept Thorac Surg, TR-06070 Ankara, Turkiye
[2] Ankara Univ, Fac Med, Dept Radiol, TR-06230 Ankara, Turkiye
[3] Ankara Univ, Fac Dent, Med Design Applicat & Res Ctr MEDITAM, TR-06070 Ankara, Turkiye
[4] Ankara Univ, Fac Med, Dept Pathol, TR-06070 Ankara, Turkiye
[5] Ankara Univ, Fac Med, Dept Radiol, TR-06070 Ankara, Turkiye
[6] Gulhane Training & Res Hosp, TR-06010 Ankara, Turkiye
来源
APPLIED SCIENCES-BASEL | 2024年 / 14卷 / 20期
关键词
lung cancer; <italic>EGFR</italic> mutation; biomarkers; computed tomography; radiomics; BIOPSY; HETEROGENEITY; OSIMERTINIB;
D O I
10.3390/app14209367
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Background: Detecting molecular drivers is crucial in the management of non-small-cell lung cancer (NSCLC). This study aimed to evaluate the use of pretreatment chest computed tomography (CT) radiomics features for predicting epidermal growth factor receptor (EGFR) mutation status in NSCLC. Materials and Methods: CT images were used to develop a radiomics-based model for predicting EGFR mutation status. Two different groups were formed from the dataset, namely groups for training (n = 380) and testing (n = 86). Feature selection was performed using the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm on a radiomics platform. Machine learning methods were then applied to construct the radiomics models. Receiver operating characteristic curve analysis was conducted to assess the performance of the radiomics signature across different datasets and methods. Results: The frequency of EGFR mutation was 13.5% (58/430). A total of 1409 quantitative imaging features were extracted from CT images using the Radcloud platform. Among the six radiomics-based classifiers (k-Nearest Neighbor, Support Vector Machine (SVM), eXtreme Gradient Boosting, Random Forest, Logistic Regression, and Decision Tree), SVM demonstrated the highest area under the curve values in both the testing and training groups, reaching 0.87 and 0.98, respectively. Our model, which incorporated both clinical and radiomics data, successfully predicted EGFR mutation status with an accuracy rate of 86.9%. Conclusion: Our findings highlight the potential of radiomics features as a non-invasive predictive imaging biomarker for EGFR mutation status, which could enhance personalized treatment in NSCLC. Radiomics emerges as a valuable tool for identifying driver mutations, although further studies are necessary to validate its clinical utility in NSCLC.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer
    Peter T. Reissmann
    Hironobu Koga
    Robert A. Figlin
    E. Carmack Holmes
    Dennis J. Slamon
    Journal of Cancer Research and Clinical Oncology, 1999, 125 : 61 - 70
  • [22] Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
    Zhao, Mengmeng
    Zhang, Jian
    Gao, Jie
    Wang, Jianping
    Ma, Zhenkai
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025, 14 (01): : 5 - 10
  • [23] Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
    Makimoto, Go
    Ohashi, Kadoaki
    Senoo, Satoru
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNAL MEDICINE, 2019, 58 (11) : 1625 - 1627
  • [24] Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng
    Cho, Byoung-Chul
    Soo, Ross A.
    LUNG CANCER, 2016, 93 : 59 - 68
  • [25] Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
    Van Der Steen, Nele
    Giovannetti, Elisa
    Carbone, Daniela
    Leonetti, Alessandro
    Rolfo, Christian D.
    Peters, Godefridus J.
    CANCER DRUG RESISTANCE, 2018, 1 (04) : 230 - 249
  • [26] Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Pietras, Richard J.
    Finn, Richard S.
    Kamranpour, Naeimeh
    Pitts, Sharon
    Marquez-Garban, Diana C.
    Desai, Amrita J.
    Dering, Judy
    Hosmer, Wylie
    von Euw, Erika M.
    Dubinett, Steven M.
    Slamon, Dennis J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 270 - 278
  • [27] Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience
    Vaguliene, Neringa
    Zemaitis, Marius
    Sarauskas, Valdas
    Vitkauskiene, Astra
    Miliauskas, Skaidrius
    Sakalauskas, Raimundas
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [28] Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer
    Jakobsen, Jan Nyrop
    Santoni-Rugiu, Eric
    Sorensen, Jens Benn
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 131 - 137
  • [29] Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
    Hiroshi Nokihara
    Hirokazu Ogino
    Atsushi Mitsuhashi
    Kensuke Kondo
    Ei Ogawa
    Ryohiko Ozaki
    Yohei Yabuki
    Hiroto Yoneda
    Kenji Otsuka
    Yasuhiko Nishioka
    BMC Cancer, 22
  • [30] Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
    Tone, Mari
    Inomata, Minoru
    Awano, Nobuyasu
    Kuse, Naoyuki
    Jo, Tatsunori
    Yoshimura, Hanako
    Minami, Jonsu
    Takada, Kohei
    Miyamoto, Shingo
    Izumo, Takehiro
    ANTICANCER RESEARCH, 2020, 40 (04) : 2239 - 2246